Express News | HC Wainwright & Co. Reiterates Buy on Lexeo Therapeutics, Maintains $22 Price Target

Benzinga52minutes ago

H.C. Wainwright Maintains Lexeo Therapeutics(LXEO.US) With Buy Rating, Maintains Target Price $22

H.C. Wainwright analyst Mitchell Kapoor maintains $Lexeo Therapeutics(LXEO.US)$ with a buy rating, and maintains the target price at $22.According to TipRanks data, the analyst has a success rate of 4

Moomoo News06:34 ET · Ratings

Analysts Are Bullish on These Healthcare Stocks: Instil Bio (TIL), Lexeo Therapeutics, Inc. (LXEO)

TipRanks06:20 ET

Express News | Lexeo Therapeutics Inc : Leerink Partners Raises Target Price to $22 From $19

Reuters23:50 ET

Lexeo Therapeutics (LXEO.US) achieved positive results in the clinical trial of gene therapy LX2006.

On July 16th, Lexeo Therapeutics (LXEO.US) announced positive mid-stage data for its gene therapy LX2006, which is being developed to treat Friedreich's ataxia (FA) cardiomyopathy.

Zhitong Finance22:55 ET

Chardan Capital Maintains Buy on Lexeo Therapeutics, Maintains $23 Price Target

Chardan Capital analyst Geulah Livshits maintains Lexeo Therapeutics (NASDAQ:LXEO) with a Buy and maintains $23 price target.

Benzinga22:46 ET